<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159821">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01984294</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-337-0133</org_study_id>
    <nct_id>NCT01984294</nct_id>
  </id_info>
  <brief_title>Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin or GS-9669 250 mg or GS-9669 500 mg in Naive or Treatment-Experienced Cirrhotic Subjects With Chronic Genotype 1 HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the antiviral efficacy of sofosbuvir (SOF)/ledipasvir (LDV)
      fixed-dose combination (FDC) plus ribavirin (RBV) or SOF/LDV plus GS-9669 in treatment-naive
      or treatment-experienced participants with chronic genotype 1 HCV infection.  A total of 90
      participants are planned to be enrolled in the study for 8 weeks of treatment, approximately
      60 having had prior treatment with a regiment containing pegylated interferon (PEG) and RBV
      for ≥ 12 weeks. Randomization will be stratified by treatment-naive versus
      treatment-experienced and by HCV genotype (1a versus 1b).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</measure>
    <time_frame>Post-treatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ; ie, &lt; 25 IU/mL) 12 weeks following the last dose of study medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants who discontinue study drug due to an adverse event</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with sustained virologic response (SVR) at 2, 4, 8, and 24 weeks after discontinuation of therapy (SVR2, SVR4, SVR8, and SVR24)</measure>
    <time_frame>Post-treatment Weeks 2, 4, 8, and 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants experiencing viral breakthrough</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Viral breakthrough is defined as HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ while receiving treatment, confirmed with 2 consecutive values (second confirmation value could be posttreatment), or last available on-treatment measurement with no subsequent follow-up values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants experiencing viral relapse</measure>
    <time_frame>Week 8 to post-treatment Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Viral relapse is defined as HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Chronic HCV Infection</condition>
  <arm_group>
    <arm_group_label>SOF/LDV+RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SOF/LDV plus RBV for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF/LDV+GS-9669 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SOF/LDV plus GS-9669 250 mg for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF/LDV+GS-9669 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SOF/LDV plus GS-9669 500 mg for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF/LDV</intervention_name>
    <description>sofosbuvir (SOF) 400 mg/ledipasvir (LDV) 90 mg fixed dose combination (FDC) tablet administered orally once daily</description>
    <arm_group_label>SOF/LDV+RBV</arm_group_label>
    <arm_group_label>SOF/LDV+GS-9669 250 mg</arm_group_label>
    <arm_group_label>SOF/LDV+GS-9669 500 mg</arm_group_label>
    <other_name>GS-7977/GS-5885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)</description>
    <arm_group_label>SOF/LDV+RBV</arm_group_label>
    <other_name>Ribasphere®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9669</intervention_name>
    <description>GS-9669 250 mg tablet(s) administered orally once daily</description>
    <arm_group_label>SOF/LDV+GS-9669 250 mg</arm_group_label>
    <arm_group_label>SOF/LDV+GS-9669 500 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18, with chronic genotype 1 HCV infection

          -  Documented HCV treatment-naïve or treatment-experienced subjects who failed previous
             PEG+RBV regimen

          -  HCV RNA &gt; 10,000 IU/mL at Screening

          -  Presence of compensated cirrhosis

          -  Screening laboratory values within defined thresholds

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner

          -  Co-infection with HIV or hepatitis B virus (HBV)

          -  Current or prior history of clinical hepatic decompensation

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Hyland, DPhil</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>November 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV genotype 1</keyword>
  <keyword>HCV</keyword>
  <keyword>Sustained Virologic Response</keyword>
  <keyword>Direct-Acting Antiviral</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>GS-7977</keyword>
  <keyword>GS-5885</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Open Label</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>Treatment-Naive</keyword>
  <keyword>Protease Inhibitors</keyword>
  <keyword>PI</keyword>
  <keyword>Treatment experienced</keyword>
  <keyword>Cirrhotic</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
